Senores Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹633cr+58.9% on FY25
EBITDA: ₹168cr+87.6% on FY25
Net profit: ₹122cr+108.3% on FY25
EPS: ₹26.39+63.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	722	633	398
	33.2	47.1	19.3
	755	680	418
	124	114	91.6
	145	137	89.8
	−3.1	0.1	−0.8
	123	112	60.4
	29.7	25.0	21.6
	37.3	31.3	16.8
	121	100	67.5
	576	521	347
	213	168	89.7
	176	137	72.9
Profit
	179	159	70.6
	179	159	70.6
	26.2	19.9	15.6
	15.5	17.6	−3.3
	41.7	37.6	12.2
	137	122	58.3
	137	122	58.3
	41.0	29.2	−3.5
	178	151	54.8
	139	122	—
	−1.2	0.0	—
Per share
	₹30.71	₹26.39	₹16.12
	₹30.67	₹26.39	₹16.12
Other comprehensive income — detail
	41.0	29.2	−3.5
	—	−0.0	—
	0.1	0.0	—
	40.9	29.2	—
	0.0	0.0	3.5
Per share — as-filed variants
	₹30.71	₹26.39	₹16.12
	₹30.67	₹26.39	₹16.12
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	457	381	218
	63.2%	60.2%	54.6%
Adjusted (ex-exceptional items) — derived
	179	159	70.6
	137	122	58.3
	₹30.71	₹26.39	₹16.12

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SENORES₹1,324.30

Senores Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSANOFI INNOVACAP MOREPENLAB IOLCP FDC PGHL SANOFICONR ORCHPHARMAMcap ₹6,098 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	398.3	632.6	722.3
Other Income	19.3	47.1	33.2
Total Income	417.5	679.7	755.5
Expenses
+ Cost of Materials Consumed	91.6	114.3	123.6
+ Purchases of Stock-in-Trade	89.8	137.3	145.0
+ Changes in Inventories	-0.8	0.1	-3.1
+ Employee Benefit Expense	60.4	112.3	123.3
+ Finance Costs	21.6	25.0	29.7
+ Depreciation & Amortisation	16.8	31.3	37.3
+ Other Expenses	67.5	100.4	120.5
Total Expenses	346.9	520.6	576.5
EBITDA	89.7	168.3	212.9
EBIT	72.9	137.1	175.6
Profit
PBT before Exceptional Items	70.6	159.1	179.0
Pretax Income	70.6	159.1	179.0
+ Current Tax	15.6	19.9	26.2
+ Deferred Tax	-3.3	17.6	15.5
Tax Expense	12.2	37.6	41.7
Net Income	58.3	121.5	137.3
+ Net Income — Continuing Ops	58.3	121.5	137.3
+ Other Comprehensive Income	-3.5	29.2	41.0
Total Comprehensive Income	54.8	150.7	178.3
Net Income to Common	—	121.5	138.5
Minority Interest	—	0.0	-1.2
Per Share
Basic EPS	16.12	26.39	30.71
Diluted EPS	16.12	26.39	30.67
Other Comprehensive Income — detail
+ Other Comprehensive Income	-3.5	29.2	41.0
+ Items NOT to be Reclassified to P&L	—	-0.0	—
+ Tax on Items NOT to be Reclassified	—	0.0	0.1
+ Items to be Reclassified to P&L	—	29.2	40.9
+ Tax on Items to be Reclassified	3.5	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	16.12	26.39	30.71
Diluted EPS — Continuing Operations	16.12	26.39	30.67
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	217.6	381.0	456.8
Gross Margin %	54.63	60.22	63.24
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	70.6	159.1	179.0
Net Income Adj (tax-effected)	58.3	121.5	137.3
EPS Adj	16.12	26.39	30.71
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00
Paid Up Equity Capital	46.1	46.1	46.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.